Thrombocytopenia and its association with mortality in patients with COVID‐19

Background Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), which causes novel coronavirus disease 2019 (COVID‐19), is spreading rapidly around the world. Thrombocytopenia in patients with COVID‐19 has not been fully studied. Objective To describe thrombocytopenia in patients with COVID...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of thrombosis and haemostasis Ročník 18; číslo 6; s. 1469 - 1472
Hlavní autoři: Yang, Xiaobo, Yang, Qingyu, Wang, Yaxin, Wu, Yongran, Xu, Jiqian, Yu, Yuan, Shang, You
Médium: Journal Article
Jazyk:angličtina
Vydáno: England Elsevier Limited 01.06.2020
International Society on Thrombosis and Haemostasis. Published by Elsevier Inc
Témata:
Aged
Betacoronavirus - pathogenicity
Brief Report
China
Coronaviridae
Coronavirus Infections - blood
Coronavirus Infections - diagnosis
Coronavirus Infections - mortality
Coronavirus Infections - virology
Coronaviruses
COVID-19
Disease transmission
Female
generalized linear model
Hospital Mortality
Humans
Male
Middle Aged
Mortality
Pandemics
Platelet Count
Platelets
Pneumonia, Viral - blood
Pneumonia, Viral - diagnosis
Pneumonia, Viral - mortality
Pneumonia, Viral - virology
Prognosis
Retrospective Studies
Risk Assessment
Risk Factors
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Thrombocytopenia
Thrombocytopenia - blood
Thrombocytopenia - diagnosis
Thrombocytopenia - mortality
Thrombocytopenia - virology
China
COVID-19
generalized linear model
mortality
SARS-CoV-2
thrombocytopenia
ISSN:1538-7933, 1538-7836, 1538-7836
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Background Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), which causes novel coronavirus disease 2019 (COVID‐19), is spreading rapidly around the world. Thrombocytopenia in patients with COVID‐19 has not been fully studied. Objective To describe thrombocytopenia in patients with COVID‐19. Methods For each of 1476 consecutive patients with COVID‐19 from Jinyintan Hospital, Wuhan, China, nadir platelet count during hospitalization was retrospectively collected and categorized into (0, 50], (50, 100], (100‐150], or (150‐) groups after taking the unit (×109/L) away from the report of nadir platelet count. Nadir platelet counts and in‐hospital mortality were analyzed. Results Among all patients, 238 (16.1%) patients were deceased and 306 (20.7%) had thrombocytopenia. Compared with survivors, non‐survivors were older, were more likely to have thrombocytopenia, and had lower nadir platelet counts. The in‐hospital mortality was 92.1%, 61.2%, 17.5%, and 4.7% for (0, 50], (50, 100], (100‐150], and (150‐) groups, respectively. With (150‐) as the reference, nadir platelet counts of (100‐150], (50, 100], and (0, 50] groups had a relative risk of 3.42 (95% confidence interval [CI] 2.36‐4.96), 9.99 (95% CI 7.16‐13.94), and 13.68 (95% CI 9.89‐18.92), respectively. Conclusions Thrombocytopenia is common in patients with COVID‐19, and it is associated with increased risk of in‐hospital mortality. The lower the platelet count, the higher the mortality becomes.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ISSN:1538-7933
1538-7836
1538-7836
DOI:10.1111/jth.14848